Organisation: Amgen

FTC settles Amgen/Horizon challenge

Amgen and Horizon Therapeutics can proceed with their $27.8 billion merger after entering a settlement with the Federal Trade Commission that prevents the new company from bundling Horizon’s rare disease treatments.

05 September 2023

Amgen, Horizon accuse FTC of trying to dodge constitutionality challenge

The Federal Trade Commission is attempting to prevent an Illinois federal court from hearing arguments that its administrative proceedings violate the Constitution, Amgen and Horizon Therapeutics have said.

14 August 2023

Amgen: FTC fabricated challenge against Horizon deal

Amgen has hit out at the Federal Trade Commission’s bid to block its vertical acquisition of Horizon Therapeutics, claiming the agency has no support for its “made up” allegations.

13 June 2023

FTC advances new theories in rare pharma challenge

Amgen is incentivised to use its control of several blockbuster medications to entrench Horizon Therapeutics' monopolies over gout and eye disease treatments, the Federal Trade Commission has alleged in suing to block the $27.8 billion merger.

17 May 2023

Unlock unlimited access to all Global Competition Review content